| 000 | 01283 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513025134.0 | ||
| 264 | 0 | _c19810413 | |
| 008 | 198104s 0 0 eng d | ||
| 022 | _a0361-5960 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aErvin, T J | |
| 245 | 0 | 0 |
_aPhase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). _h[electronic resource] |
| 260 |
_bCancer treatment reports _c |
||
| 300 |
_a1067-71 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAspartic Acid _xanalogs & derivatives |
| 650 | 0 | 4 |
_aDiarrhea _xchemically induced |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Parenteral |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMucous Membrane _xdrug effects |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOrganophosphorus Compounds _xtoxicity |
| 650 | 0 | 4 |
_aPhosphonoacetic Acid _xanalogs & derivatives |
| 650 | 0 | 4 |
_aSkin Diseases _xchemically induced |
| 700 | 1 | _aBlum, R H | |
| 700 | 1 | _aMeshad, M W | |
| 700 | 1 | _aKufe, D W | |
| 700 | 1 | _aJohnson, R K | |
| 700 | 1 | _aCanellos, G P | |
| 773 | 0 |
_tCancer treatment reports _gvol. 64 _gno. 10-11 _gp. 1067-71 |
|
| 999 |
_c7459375 _d7459375 |
||